BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28079159)

  • 1. SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression.
    Berzaghi R; Maia VS; Pereira FV; Melo FM; Guedes MS; Origassa CS; Scutti JB; Matsuo AL; Câmara NO; Rodrigues EG; Travassos LR
    Sci Rep; 2017 Jan; 7():40585. PubMed ID: 28079159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs.
    Song S; Wang Y; Wang J; Lian W; Liu S; Zhang Z; Liu F; Wei L
    Eur J Cancer; 2012 Sep; 48(14):2252-9. PubMed ID: 22230748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibiting effect of IL-10 in tumor microenvironment on anti-tumor activity of SOCS1-silenced DC vaccine].
    Wang Z; You H; Song S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Apr; 29(4):379-83. PubMed ID: 23643168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of SOCS1 silencing on proliferation and apoptosis of melanoma cells: An in vivo and in vitro study.
    Yu SJ; Long ZW
    Tumour Biol; 2017 May; 39(5):1010428317694315. PubMed ID: 28466787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma cell-secreted exosomal miR-155-5p induce proangiogenic switch of cancer-associated fibroblasts via SOCS1/JAK2/STAT3 signaling pathway.
    Zhou X; Yan T; Huang C; Xu Z; Wang L; Jiang E; Wang H; Chen Y; Liu K; Shao Z; Shang Z
    J Exp Clin Cancer Res; 2018 Oct; 37(1):242. PubMed ID: 30285793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation gene expression of miR200c and ZEB1 positively enhances effect of tumor vaccine B16F10/GPI-IL-21 on inhibition of melanoma growth and metastasis.
    Wang X; He X; Zhao F; Wang J; Zhang H; Shi F; Zhang Y; Cai K; Dou J
    J Transl Med; 2014 Mar; 12():68. PubMed ID: 24625224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of suppressors of cytokine signaling 1 inhibition of epithelial-mesenchymal transition signaling through ROS regulation in colon cancer cells: suppression of Src leading to thioredoxin up-regulation.
    Jung SH; Kim SM; Lee CE
    Oncotarget; 2016 Sep; 7(38):62559-62571. PubMed ID: 27613835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.
    Ren D; Yang Q; Dai Y; Guo W; Du H; Song L; Peng X
    Mol Cancer; 2017 Jul; 16(1):117. PubMed ID: 28693582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1.
    Gui Y; Khan MGM; Bobbala D; Dubois C; Ramanathan S; Saucier C; Ilangumaran S
    World J Gastroenterol; 2017 Sep; 23(36):6639-6649. PubMed ID: 29085209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-29a suppresses the invasion and migration of osteosarcoma cells by regulating the SOCS1/NF-κB signalling pathway through negatively targeting DNMT3B.
    Gong HL; Tao Y; Mao XZ; Song DY; You D; Ni JD
    Int J Mol Med; 2019 Oct; 44(4):1219-1232. PubMed ID: 31364725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.
    Mathieu MG; Miles AK; Ahmad M; Buczek ME; Pockley AG; Rees RC; Regad T
    Cell Death Dis; 2014 Feb; 5(2):e1061. PubMed ID: 24525737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.
    Yu W; Hua Y; Qiu H; Hao J; Zou K; Li Z; Hu S; Guo P; Chen M; Sui S; Xiong Y; Li F; Lu J; Guo W; Luo G; Deng W
    Cell Death Dis; 2020 Jul; 11(7):506. PubMed ID: 32632098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
    Villalobos-Hernandez A; Bobbala D; Kandhi R; Khan MG; Mayhue M; Dubois CM; Ferbeyre G; Saucier C; Ramanathan S; Ilangumaran S
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):36-47. PubMed ID: 27779203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4⁺ and CD8⁺ T cells.
    Guenterberg KD; Lesinski GB; Mundy-Bosse BL; Karpa VI; Jaime-Ramirez AC; Wei L; Carson WE
    Cancer Immunol Immunother; 2011 Sep; 60(9):1281-8. PubMed ID: 21604070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma.
    Lin L; Chen S; Wang H; Gao B; Kallakury B; Bhuvaneshwar K; Cahn K; Gusev Y; Wang X; Wu Y; Marshall JL; Zhi X; He AR
    Theranostics; 2021; 11(9):4232-4250. PubMed ID: 33754058
    [No Abstract]   [Full Text] [Related]  

  • 18. REX1 promotes EMT-induced cell metastasis by activating the JAK2/STAT3-signaling pathway by targeting SOCS1 in cervical cancer.
    Zeng YT; Liu XF; Yang WT; Zheng PS
    Oncogene; 2019 Oct; 38(43):6940-6957. PubMed ID: 31409905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Immunomodulatory Gallotanin-Rich Fraction From
    Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S
    Front Immunol; 2020; 11():584959. PubMed ID: 33312174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
    Tang Q; Jiang J; Liu J
    Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.